

FOR IMMEDIATE RELEASE

TSX VENTURE: HTL



HAMILTON THORNE TO ANNOUNCE Q1 2017 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON MAY 25

BEVERLY, MA and TORONTO, Ontario – May 22, 2017 – Hamilton Thorne Ltd. (TSX-V: HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it will release its first quarter financial results for the three months ended March 31, 2017 before the market opens on Thursday, May 25, 2017. The press release, with accompanying financial information, will be posted on the Company's website at www.hamiltonthorne.com and on www.sedar.com.

The Company will follow with a conference call Thursday, May 25, 2017, at 11:00 a.m. EDT to review highlights of its quarterly results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 28240640. A recording of the call will be available on Hamilton Thorne's website five business days after the call.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne is a leading world-wide provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Its image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields. Hamilton Thorne's standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics. Hamilton Thorne's growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Cook Medical, Novartis, Pfizer, and Dow Chemical.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com

Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com